CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Bictegravir

比克替拉韦 杂质对照品Bictegravir Impurities

33 个杂质条目33 impurity entries

本页汇总 比克替拉韦 的 33 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 33 impurity reference standards of Bictegravir. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 比克替拉韦(Bictegravir)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesDetermination and quantification of related substances and degradation products in bictegravir by full factorial design evaluated HPLC and mass spectrometry
    Analytical methods : advancing methods and applications · 2023 · Kumar SRJ et al.  ·  PMID 36852477  ·  DOI
  2. 杂质研究Impurity studiesDevelopment and Validation of a Stability-Indicating RP-HPLC Method for the Simultaneous Estimation of Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate
    Turkish journal of pharmaceutical sciences · 2021 · Attaluri T et al.  ·  PMID 34496481  ·  DOI
  3. 杂质研究Impurity studiesComprehensive Review on Different Analytical Techniques for HIV 1- Integrase Inhibitors: Raltegravir, Dolutegravir, Elvitegravir and Bictegravir
    Critical reviews in analytical chemistry · 2024 · Jain P et al.  ·  PMID 35617468  ·  DOI
  4. 分析方法Analytical MethodsDevelopment, validation and clinical implementation of a HPLC-MS/MS method for the simultaneous quantification of bictegravir, emtricitabine, doravirine, cabotegravir, lenacapavir, fostemsavir, tenofovir alafenamide and the corresponding metabolites temsavir and tenofovir, in human plasma
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2025 · Mattino A et al.  ·  PMID 41072339  ·  DOI
  5. 分析方法Analytical MethodsValidation of an LC-MS/MS assay for the simultaneous determination of bictegravir, doravirine, and raltegravir in human plasma
    Journal of pharmaceutical and biomedical analysis · 2022 · Schauer AP et al.  ·  PMID 36030752  ·  DOI

比克替拉韦 —— 原料药与杂质对照品Bictegravir — drug substance & impurities

共 34 个条目(含原料药本体)34 items incl. the drug substance
Bictegravir structure
原料药 APIAPI
比克替拉韦Bictegravir
Bictegravir
CAS No.1611493-60-7
Chemical FormulaC21H18F3N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 1 structure
1
比克替拉韦杂质1Bictegravir Impurity 1
Bictegravir Impurity 1
CAS No.1616342-45-0
Chemical FormulaC15H16N2O6
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 2 structure
2
比克替拉韦杂质2Bictegravir Impurity 2
Bictegravir Impurity 2
CAS No.1616340-94-3
Chemical FormulaC22H20F3N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 3 structure
3
比克替拉韦杂质3Bictegravir Impurity 3
Bictegravir Impurity 3
CAS No.1616339-90-2
Chemical FormulaC21H20FN3O5
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 4 structure
4
比克替拉韦杂质4Bictegravir Impurity 4
Bictegravir Impurity 4
CAS No.214759-21-4
Chemical FormulaC7H6F3N
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 5 structure
5
比克替拉韦杂质5Bictegravir Impurity 5
Bictegravir Impurity 5
CAS No.1616339-82-2
Chemical FormulaC21H20FN3O5
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 6 structure
6
比克替拉韦杂质6Bictegravir Impurity 6
Bictegravir Impurity 6
CAS No.1611493-56-1
Chemical FormulaC21H19F2N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 7 structure
7
比克替拉韦杂质7Bictegravir Impurity 7
Bictegravir Impurity 7
CAS No.1616340-13-6
Chemical FormulaC21H19F2N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 8 structure
8
比克替拉韦杂质8Bictegravir Impurity 8
Bictegravir Impurity 8
CAS No.2365156-61-0
Chemical FormulaC21H18F3N3O9S
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 10 structure
10
比克替拉韦杂质10Bictegravir Impurity 10
Bictegravir Impurity 10
CAS No.2365156-60-9
Chemical FormulaC27H26F3N3O11
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 12 structure
12
比克替拉韦杂质12Bictegravir Impurity 12
Bictegravir Impurity 12
CAS No.1616340-12-5
Chemical FormulaC21H18F3N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 13 structure
13
比克替拉韦杂质13Bictegravir Impurity 13
Bictegravir Impurity 13
CAS No.1335210-23-5
Chemical FormulaC13H17NO8
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 14 structure
14
比克替拉韦杂质14Bictegravir Impurity 14
Bictegravir Impurity 14
CAS No.2411506-37-9
Chemical FormulaC5H9NO·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 15 structure
15
比克替拉韦杂质15Bictegravir Impurity 15
Bictegravir Impurity 15
CAS No.2411506-35-7
Chemical FormulaC13H15NO3
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 16 structure
16
比克替拉韦杂质16Bictegravir Impurity 16
Bictegravir Impurity 16
CAS No.1846582-14-6
Chemical FormulaC21H18F3N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 18 structure
18
比克替拉韦杂质18Bictegravir Impurity 18
Bictegravir Impurity 18
CAS No.2365156-62-1
Chemical FormulaC21H18F3N3O6
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 21 structure
21
比克替拉韦杂质21Bictegravir Impurity 21
Bictegravir Impurity 21
CAS No.1259436-59-3
Chemical FormulaC5H11NO·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 22 structure
22
比克替拉韦杂质22Bictegravir Impurity 22
Bictegravir Impurity 22
CAS No.124555-33-5
Chemical FormulaC5H11NO·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 23 structure
23
比克替拉韦杂质23Bictegravir Impurity 23
Bictegravir Impurity 23
CAS No.1523530-42-8
Chemical FormulaC5H11NO·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 24 structure
24
比克替拉韦杂质24Bictegravir Impurity 24
Bictegravir Impurity 24
CAS No.204913-01-9
Chemical FormulaC12H21NO3
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 25 structure
25
比克替拉韦杂质25Bictegravir Impurity 25
Bictegravir Impurity 25
CAS No.225641-82-7
Chemical FormulaC12H21NO4
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 26 structure
26
比克替拉韦杂质26Bictegravir Impurity 26
Bictegravir Impurity 26
CAS No.167465-99-8
Chemical FormulaC10H19NO3
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 33 structure
33
比克替拉韦杂质33Bictegravir Impurity 33
Bictegravir Impurity 33
CAS No.2411332-67-5
Chemical FormulaC14H11F5N2
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 39 structure
39
比克替拉韦杂质39Bictegravir Impurity 39
Bictegravir Impurity 39
CAS No.1616340-93-2
Chemical FormulaC15H16N2O6
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 43 structure
43
比克替拉韦杂质43Bictegravir Impurity 43
Bictegravir Impurity 43
CAS No.2755911-69-2
Chemical FormulaC15H16N2O6
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 46 structure
46
比克替拉韦杂质46Bictegravir Impurity 46
Bictegravir Impurity 46
CAS No.1616340-97-6
Chemical FormulaC22H20F3N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 47 structure
47
比克替拉韦杂质47Bictegravir Impurity 47
Bictegravir Impurity 47
CAS No.2408611-21-0
Chemical FormulaC22H20F3N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 50 structure
50
比克替拉韦杂质50Bictegravir Impurity 50
Bictegravir Impurity 50
CAS No.1846582-19-1
Chemical FormulaC22H20F3N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 58 structure
58
比克替拉韦杂质58Bictegravir Impurity 58
Bictegravir Impurity 58
CAS No.1616342-10-9
Chemical FormulaC22H21F2N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 65 structure
65
比克替拉韦杂质65Bictegravir Impurity 65
Bictegravir Impurity 65
CAS No.3028279-46-8
Chemical FormulaC21H18F3N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 72 structure
72
比克替拉韦杂质72Bictegravir Impurity 72
Bictegravir Impurity 72
CAS No.2651309-06-5
Chemical FormulaC12H15NO8
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 73 structure
73
比克替拉韦杂质73Bictegravir Impurity 73
Bictegravir Impurity 73
CAS No.948831-27-4
Chemical FormulaC12H21NO3
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 78 structure
78
比克替拉韦杂质78Bictegravir Impurity 78
Bictegravir Impurity 78
CAS No.2408611-30-1
Chemical FormulaC22H20F3N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Bictegravir Impurity 81 structure
81
比克替拉韦杂质81Bictegravir Impurity 81
Bictegravir Impurity 81
CAS No.1616340-76-1
Chemical FormulaC15H16N2O6
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

比克替拉韦 —— 研究文献与合成路线Bictegravir — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 比克替拉韦 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Bictegravir. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Determination and quantification of related substances and degradation products in bictegravir by full factorial design evaluated HPLC and mass spectrometry
    Kumar SRJ, Rao VK, Katari NK, et al. · Analytical methods : advancing methods and applications · 2023 · 被引 1cited 1
  2. A green approach for the analysis of emtricitabine bictegravir and tenofovir in a pharmaceutical preparation using novel HPLC and spectrophotometric methods
    Tiris G, Genc AA, Oven E, et al. · Biomedical chromatography : BMC · 2023

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

比克替拉韦 杂质谱研究要点Bictegravir — impurity profiling notes

下面这些是拿到 比克替拉韦 的 34 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 34 impurity entries for Bictegravir, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances